Acrux Limited

Equities

ACR

AU000000ACR3

Pharmaceuticals

Market Closed - Australian S.E. 02:10:05 2024-04-29 am EDT 5-day change 1st Jan Change
0.061 AUD +1.67% Intraday chart for Acrux Limited +1.67% +38.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Acrux, TruPharma Launch Dapsone 5% Gel in US MT
Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024
Acrux Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Acrux Gets AU$3 Million Tax Rebate for Fiscal Year 2023 MT
Transcript : Acrux Limited, 2023 Earnings Call, Aug 31, 2023
Acrux Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Acrux Files US FDA Application for Generic Topical Medication; Shares Jump 7% MT
Australian Shares Retreat Anew on Rate Hike, Slower-than-Expected GDP Growth MT
Acrux Secures US FDA Approval for Generic Version of Topical Drug MT
Acrux Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
IT, Energy Stocks Push Australian Benchmark to Nine-Month High MT
Acrux Selling Lenzetto Royalties for AU$6.4 Million MT
Acrux Announces Gedeon Richter Buyout of Future Lenzetto Royalties for EUR 4.1 Million CI
Acrux Gets Favorable Outcome in US FDA Assessment MT
Higher Oil, Gold Prices Send Australian Shares Back to Positive Territory MT
Acrux Launches Generic Topical Anesthesia Cream in the US; Shares Jump 7% MT
Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States CI
Acrux, Amring Pharmaceuticals Terminate Co-Development Deal for Generic Topical Product for US Market MT
Acrux Limited and Amring Pharmaceuticals Inc. Announce Mutual Termination of Co-Development Agreement CI
Australian Tax Office Grants Overseas Finding Claim for Acrux Subsidiary MT
Acrux Receives $1.5 Million R&D Tax Rebate MT
Acrux Gets R&D Tax Refund MT
Acrux Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Acrux Awaits Potential US FDA Approval for New Drug Application MT
Acrux's Sixth Generic Dossier Accepted by FDA for Review CI
Chart Acrux Limited
More charts
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto(estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ACR Stock
  4. News Acrux Limited
  5. Acrux Secures US FDA Approval for Generic Version of Topical Drug